Abstract:Cisplatin resistance plays a significant role in the dismal prognosis and progression of muscle-invasive bladder cancer (MIBC). However, the strategies to predict prognosis and cisplatin resistance are inefficient, and it remains unclear whether cisplatin resistance is associated with tumor immunity. In this study, we integrated the transcriptional data from cisplatin-resistant cell lines and a TCGA-MIBC cohort to establish cisplatin-resistance-related cluster classification and a cisplatin-resistance-related gene risk score (CRRGRS). Kaplan–Meier survival curves showed that compared with those in low CRRGRS group, MIBC patients belonging to high CRRGRS group had worse prognosis in TCGA-MIBC cohort and external GEO cohorts. Meanwhile, CRRGRS was able to help forecast chemotherapy and immunotherapy response of MIBC patients in the TGCA cohort and IMvigor210 cohort. Moreover, compared with the low CRRGRS group, the high CRRGS group possessed a relatively immunosuppressive “cold tumor” phenotype with a higher tumor immune dysfunction and exclusion (TIDE) score, ESTIMATE score, stromal score and immune score and a lower immunophenoscore (IPS) score. The upregulated expression levels of immune checkpoint genes, including PD-1, PD-L1 and CTLA4, in the high CRRGRS group also further indicated that a relative immunosuppressive tumor microenvironment may exist in MIBC patients belonging to high CRRGRS group. In addition, we integrated CRRGRS and clinical characteristics with prognostic value to develop a nomogram, which could help forecast overall survival of MIBC patients. Furthermore, DIAPH3 was identified as a regulator of proliferation and cisplatin resistance in MIBC. The expression of DIAPH3 was increased in cisplatin-resistant cell lines and chemotherapy-unsensitive people. Further mechanism exploration revealed that DIAPH3 facilitated tumor proliferation and cisplatin resistance by regulating the NF-kB and epithelial-mesenchymal transition (EMT) pathways. In conclusion, the comprehensive investigations of CRRGRS increased the understanding of cisplatin resistance and provided promising insights to restrain tumor growth and overcome chemoresistance by targeting DIAPH3.

[Relationship between BRCA1 mRNA expression in tumor cells from malignant effusions and chemosensitivity to cisplatin in patients with metastatic malignant effusions].

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

Study on the relationship between expression levels of ERCC1 mRNA and sensitivity of tumor cells isolated from malignant effusions to cisplatin in vitro

Relationship Between Plasma BRCA1 Mrna Expression and Sensitivity to Docetaxel and Cisplatin in Gastric Cancer.

Identification of a Cisplatin Resistant-Based Prognostic Immune Related Gene Signature in MIBC

BRCA1 Mrna Expression As a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy

Expression of ERCC1 and BRCA1 Predict the Clinical Outcome of Non-Small Cell Lung Cancer in Patients Receiving Platinum-Based Chemotherapy.

First-line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients.

Effect of RRM1 and BRCA1 Expressions on Efficiency of Gemcitabine and Platinum in Patients with Advanced Non-Small Cell Lung Cancer

Prognostic Significance of ERCC1 Mrna Expression in Patients with Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

Relationship Between Mrna Expression of BRCA1 and Β-Tubulin III in Malignant Effusions and Ex Vivo Chemosenstitivity to Docetaxel

Expression of ATM , CHK 2 and BRCA 1 predicts the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy

Predictive Value of BRCA1/2 Mrna Expression for Response to Neoadjuvant Chemotherapy in BRCA‐negative Breast Cancers

Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer

Detection of Cell-Free ERCC1 and Thymidylate Synthase (TS) Mrna in Malignant Effusions and Its Association with Anticancer Drug Sensitivity.

Expression of ERCC-1 in NSCLC tissue and its value for appraising chemotherapy

Overexpression of SMARCA2 or CAMK2D is Associated with Cisplatin Resistance in Human Epithelial Ovarian Cancer

ERCC1 and BRCA1 Expressions in the Tissues of Colorectal Cancer and Its Relationship with Clinical Significance of Platinum-Based Chemotherapy

[Influences of PC cell-derived growth factor and breast cancer resistance protein on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer]

Successful personalized chemotherapy for metastatic gastric cancer based on quantitative BRCA1 mRNA expression level: A case report.

High Expression of ERCC1 is a Poor Prognostic Factor in Chinese Patients with Non-Small Cell Lung Cancer Receiving Cisplatin-Based Therapy